Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Alkaptonuria


Other Names for this Disease
  • AKU
  • Alcaptonuria
  • Alkaptonuric ochronosis
  • Homogentisic acid oxidase deficiency
  • Homogentisic acidura
More Names
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Your Question

My husband, now 44 years of age, was diagnosed with alkaptonuria 10 years ago. Until recently, he experienced discoloration of the urine, occasional stiff joints, and rupture of tendons. Now he is having breathing problems and stomach issues. Are these symptoms related to alkaptonuria? Are there any treatments for this condition? Are there dietary guidelines for individuals with alkaptonuria?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What are the signs and symptoms of alkaptonuria?

The urine of individuals with alkaptonuria turns black when exposed to air. Ochronosis, a buildup of dark pigment in connective tissues such as cartilage and skin, is also characteristic of the disorder. This blue-black pigmentation usually appears after age 30 and commonly affects the cartilage of the ear, ligaments, tendons, blood vessels, kidneys, lungs and prostate. Dark spots on the white of the eye and cornea may also occur. People with alkaptonuria typically develop arthritis, particularly in the spine and large joints, beginning in early adulthood. Other features of this condition can include heart problems, kidney stones, and prostate stones.[1][2][3]
Last updated: 8/1/2011

Are breathing problems and stomach issues commonly reported in individuals with alkaptonuria?

Breathing problems and stomach issues are not classic symptoms of alkaptonuria, although cardiovascular problems may present in later adulthood and the pigmentations associated with the condition may affect the lungs (as well as many other body systems).[1][3]
Last updated: 8/1/2011

How might alkaptonuria be treated?

There is no cure for alkaptonuria, but there is treatment for some individual signs and symptoms of the condition. Joint pain may be substantial in individuals with alkaptonuria, and close attention to pain control is usually necessary. Physical and occupational therapy can be important to promote muscle strength and flexibility. Knee, hip, and shoulder replacement surgeries may be options for managing significant arthritis. In general, however, the goal of joint replacement is pain relief rather than increased range of motion. Maintaining joint range of motion through moderate non-weight-bearing exercise such as swimming may have beneficial effects. Treatment of prostate stones and renal stones may include surgery.[4]

Several therapies for alkaptonuria have been investigated. Treatment of alkaptonuria with nitisinone (also called NTBC) has been proposed; nitisinone is currently approved for the treatment of tyrosinemia type I, which is also a metabolic disorder. Further investigations to determine the benefits of nitisinone in slowing the progression of joint disease are in progress.[4] To see a list of completed clinical trials or trials currently enrolling individuals with alkaptonuria, click here.

No therapy has proven to prevent or correct the pigmentary changes of ochronosis.[4]
Last updated: 8/1/2011

Are there any dietary guidelines for individuals with alkaptonuria?

Information supporting dietary management of alkaptonuria is limited. Dietary restriction of phenylalanine and tyrosine has been proposed to reduce the production of homogentistic acid, but severe restriction of these amino acids is not practical in the long term and may be dangerous. Nonetheless, high-protein diets should be avoided. High doses of vitamin C may decrease urinary benzoquinone acetic acid, a derivative of homogentistic acid, but do not appear to affect homogentistic acid excretion. It has been hypothesized that high-dose ascorbic acid may prevent the deposition of ochronotic pigment, although it does not alter the basic metabolic defect.[4][5]
Last updated: 8/1/2011

References